Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Healthcare Venture Investors Ante Up. Public Markets Remain Cool. -- Barrons.com
Exact Sciences, Quanterix Extend Slide After Medicare Rates
Exact Sciences Analyst Ratings
BioAge Stock Rallies 29% Following Upsized $198M IPO
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Biogen to End Sage Deal for Neuro Candidate
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO
Amgen Analyst Ratings
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen Says A Second Phase 3 Clinical Trial Is Ongoing In Japan Evaluating TEPEZZA Among Adults With Chronic TED And A Low CAS
Amgen Gets Japanese Approval of Tepezza for Thyroid Eye Disease
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Market Whales and Their Recent Bets on AMGN Options
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today